Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-035 for AKI Prevention in Cardiac Surgery
NCT05126303Phase 2Terminated
- Sponsor
- Guard Therapeutics
- Start
- Mar 2022
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in acute kidney injury (AKI) comparing RMC-035 with Placebo (2 arms). Primary endpoint: Percentage of Subjects Developing Acute Kidney Injury (AKI) at 72 hours. Started Mar 2022; status: terminated.
02
Drugs
RMC-035
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05126303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126303.